CN101809000A - 具有大麻素-cb1拮抗作用和5-羟色胺再摄取抑制作用组合的化合物 - Google Patents

具有大麻素-cb1拮抗作用和5-羟色胺再摄取抑制作用组合的化合物 Download PDF

Info

Publication number
CN101809000A
CN101809000A CN200880001916A CN200880001916A CN101809000A CN 101809000 A CN101809000 A CN 101809000A CN 200880001916 A CN200880001916 A CN 200880001916A CN 200880001916 A CN200880001916 A CN 200880001916A CN 101809000 A CN101809000 A CN 101809000A
Authority
CN
China
Prior art keywords
compound
disease
compounds
formula
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880001916A
Other languages
English (en)
Chinese (zh)
Inventor
J·H·M·朗厄
C·G·克鲁瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Priority claimed from PCT/EP2008/050181 external-priority patent/WO2008084057A1/en
Publication of CN101809000A publication Critical patent/CN101809000A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880001916A 2007-01-10 2008-01-09 具有大麻素-cb1拮抗作用和5-羟色胺再摄取抑制作用组合的化合物 Pending CN101809000A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07100323 2007-01-10
EP07100323.0 2007-01-10
PCT/EP2008/050181 WO2008084057A1 (en) 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition

Publications (1)

Publication Number Publication Date
CN101809000A true CN101809000A (zh) 2010-08-18

Family

ID=38069361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880001916A Pending CN101809000A (zh) 2007-01-10 2008-01-09 具有大麻素-cb1拮抗作用和5-羟色胺再摄取抑制作用组合的化合物

Country Status (6)

Country Link
CN (1) CN101809000A (pt)
AR (1) AR064765A1 (pt)
BR (1) BRPI0806452A2 (pt)
MX (1) MX2009007405A (pt)
SA (1) SA08280759B1 (pt)
TW (1) TW200845963A (pt)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547263A (zh) * 2010-11-18 2014-01-29 詹里恩探索公司 对于治疗代谢性疾病，包括肥胖症和糖尿病有用的大麻素受体拮抗剂/反相激动剂
CN104666291A (zh) * 2013-11-26 2015-06-03 山东绿叶制药有限公司 去甲基文拉法辛苯甲酸酯类化合物在制备改善性功能障碍药物中的应用
CN109640990A (zh) * 2016-05-25 2019-04-16 田边三菱制药株式会社 用于治疗焦虑症的(2S)-1-[4-(3,4-二氯苯基)哌啶-1-基]-3-[2-(5-甲基-1,3,4-噁二唑-2-基)苯并[b]呋喃-4-基氧基]丙-2-醇或其代谢物
CN111655265A (zh) * 2017-11-28 2020-09-11 韩国科学技术院 用于治疗肌张力障碍的新型药物组合物
CN115052868A (zh) * 2020-02-06 2022-09-13 伦敦制药与研究公司 大麻素硫酸酯、及其盐和用途
US11766430B2 (en) 2018-09-04 2023-09-26 Minerva Neurosciences, Inc. Methods of using a phenoxypropylamine compound to treat pain

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547263A (zh) * 2010-11-18 2014-01-29 詹里恩探索公司 对于治疗代谢性疾病，包括肥胖症和糖尿病有用的大麻素受体拮抗剂/反相激动剂
CN103547263B (zh) * 2010-11-18 2015-12-09 詹里恩探索公司 对于治疗代谢性疾病，包括肥胖症和糖尿病有用的大麻素受体拮抗剂/反相激动剂
CN104666291A (zh) * 2013-11-26 2015-06-03 山东绿叶制药有限公司 去甲基文拉法辛苯甲酸酯类化合物在制备改善性功能障碍药物中的应用
CN109640990A (zh) * 2016-05-25 2019-04-16 田边三菱制药株式会社 用于治疗焦虑症的(2S)-1-[4-(3,4-二氯苯基)哌啶-1-基]-3-[2-(5-甲基-1,3,4-噁二唑-2-基)苯并[b]呋喃-4-基氧基]丙-2-醇或其代谢物
CN111655265A (zh) * 2017-11-28 2020-09-11 韩国科学技术院 用于治疗肌张力障碍的新型药物组合物
CN111655265B (zh) * 2017-11-28 2024-05-10 韩国科学技术院 用于治疗肌张力障碍的新型药物组合物
US11766430B2 (en) 2018-09-04 2023-09-26 Minerva Neurosciences, Inc. Methods of using a phenoxypropylamine compound to treat pain
CN115052868A (zh) * 2020-02-06 2022-09-13 伦敦制药与研究公司 大麻素硫酸酯、及其盐和用途

Also Published As

Publication number Publication date
MX2009007405A (es) 2009-07-17
TW200845963A (en) 2008-12-01
SA08280759B1 (ar) 2011-05-04
BRPI0806452A2 (pt) 2011-09-06
AR064765A1 (es) 2009-04-22

Similar Documents

Publication Publication Date Title
US8138174B2 (en) Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
FR2735127A1 (fr) Nouvelles piperazines heteroaromatiques utiles comme medicaments.
CN101809000A (zh) 具有大麻素-cb1拮抗作用和5-羟色胺再摄取抑制作用组合的化合物
JP4740116B2 (ja) 精神疾患および神経障害の処置のための５−ｈｔ受容体アンタゴニスト
EP2091939B1 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
WO2007138050A1 (en) Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
CN108026073A (zh) 作为毒蕈碱性m1受体正向别构调节剂的氟吲哚衍生物
CA2632582A1 (en) 4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
CA2671554A1 (en) Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
US8461184B2 (en) Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
HK1143362A (en) Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
CN102112466A (zh) 具有cb1-拮抗活性的(5r)-1，5-二芳基-4，5-二氢-1h-吡唑-3-甲脒衍生物
EA032473B1 (ru) 3,5-диаминопиразоловые ингибиторы киназы
CN101848907A (zh) 具有大麻素-cb1拮抗作用和乙酰胆碱酯酶抑制作用的组合的化合物
US20080153867A1 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
CN101454291A (zh) 作为选择性大麻素cb1受体拮抗剂的含硫的吡唑衍生物
HK1129104A (en) Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists
JP2011524351A (ja) Ｃｂ１アンタゴニスト活性を有するフルオロ置換された３，４−ジアリール−４，５−ジヒドロ−１ｈ−ピラゾール−１−カルボキサミジン誘導体
FR2921063A1 (fr) Ligands des recepteurs cannabinoides
AU2008263915A1 (en) 4,5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
HK1143587A (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
CN101939300A (zh) 作为大麻素cb1受体调节剂的4,5-二氢-(1h)-吡唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1143362

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100818

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1143362

Country of ref document: HK